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INTRODUCTION
An osteosarcoma is the most common childhood malig-
nancy of the bone (1). The incidence peaks in early to middle
adolescence and the tumor is relatively rare in older patients.
According to previous reports (2, 3), despite the development
of multi-modality treatments, older patients with osteosar-
coma patients have an unfavorable prognosis. Information
related to the clinical outcome of older patients with osteosar-
coma revealed that the dismal prognosis is due to the fact that,
in older patients, osteosarcoma is likely a secondary lesion.
Many studies report that most osteosarcoma in older patients
results from a sarcomatous transformation of Paget’s disease
of the bone, or as a complication of irradiation. However, in
Korea and Japan, secondary osteosarcoma in older patients
is rare on account of the rarity of Paget’s disease in Asians. In
order to confirm the poor prognosis associated with the diag-
nosis of osteosarcoma in older patients, we identified 665 os-
teosarcoma cases treated at our hospital. Thirty-nine prima-
ry osteosarcoma cases involving patients older than 40 yr of
age and forty-three adolescent patients were included. 
The aim was to determine if a primary osteosarcoma in
patients older than 40 yr of age have different clinical features
and a poorer prognosis than adolescent patients. In addition,
assessment of the main cause for the poor survival and a pos-
sible solution were investigated.
MATERIALS AND METHODS
Review of 665 high-grade osteosarcoma patients who under-
went treatment in our hospital, between May 1985 and Sep-
tember 2002 was undertaken. Two pathologists reviewed
the microscopic slides of biopsied specimens. Patients with
osteosarcoma of the facial bone, as well as those identified as
secondary lesions were excluded. The age of over 40 yr was
selected arbitrarily in an effort to include only older patients.
Consequently, of these 665 patients, 39 (5.9%) were includ-
ed in the analysis. These older patients were compared to
forty-three adolescent patients which review of medical records
was available. The clinical information was obtained by review-
ing the medical records. The institutional review board at
our hospital accepted all protocols. Two evaluations were
performed. In the first, an attempt was made to evaluate the
possible prognostic factors such as gender, tumor location,
size, serum alkaline phosphatase level, radiological findings,
chemotherapy intensity, chemotherapy-induced tumor necro-
sis and surgical margin. The second evaluation involved deter-
mining whether any significant clinical differences existed
between older patients and adolescents.
Neo-adjuvant and adjuvant chemotherapy were given
according to Rosen’s T-10 regimen (4). Preoperative chemo-
therapy consisted of a weekly administration of high dose
methotrexate (12 g/m2) for 2 consecutive weeks, followed
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Primary Osteosarcoma in Patients Older than 40 Years of Age
Among the 665 patients who registered at our hospital, we reviewed 39 cases of
high grade primary osteosarcoma in patients who were older than 40 yr of age. The
aim of this study was to determine if a primary osteosarcoma in older patients has
different clinical features, and a poorer prognosis than in younger patients. Two
evaluations were performed. In the first, an attempt was made to determine the
possible prognostic factors such as gender, location, size, alkaline phosphatase,
radiological findings, chemotherapy intensity, chemotherapy-induced tumor necro-
sis, and surgical margin. The second evaluation involved assessment of whether
there were any significant clinical differences between older patients and adoles-
cents. According to the results, a primary osteosarcoma in older patients did not
reveal any significant prognostic variables. A primary osteosarcoma in older patients
showed a poorer prognosis due to relatively unusual locations, common abnormal
radiological findings, and a poor response to chemotherapy. Therefore, careful atten-
tion should be paid to making an accurate diagnosis and new strategies for more
effective treatment, including chemotherapy, must to be developed in order to achieve
long term survival in older patients with osteosarcoma.
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by cisplatin (100 mg/m2), and doxorubicin (30 mg/m2). Two
courses of this three-drug combination chemotherapy were
followed by definitive surgery. All of the resected tumors
were subjected to a pathological assessment for neo-adjuvant
chemotherapy response. The histological response to chemo-
therapy was graded as ‘‘good’’ (≥90% tumor necrosis) and
‘‘poor’’ (<90% tumor necrosis). The good grade correspond-
ed to grade III and IV of the descriptive classification proposed
by Rosen et al. (4). Patients whose tumor exhibited more than
90% necrosis (good responders) received the same chemother-
apeutic agents that they had been given before surgery. Pati-
ents with tumor necrosis of less than 90% (poor responders)
received cisplatin, doxorubicin, ifosfamide, and bleomycin.
Ifosfamide (14 g/m2) was infused continuously for 7days with
bleomycin (30 mg/m2). 
The event free survival was defined as the time the patients
remained free of disease (the absence of pulmonary or other
metastases and local recurrence) after the primary tumor had
been extirpated. The overall survival included all of the pati-
ents who had metastases, and were treated for this compli-
cation, and was calculated using the Kaplan-Meier survival
curves. The impact of the prognostic factors was assessed using
the log-rank test. The differences between the adolescent and
older patients were assessed using a chi-square test. A p value
<0.05 was considered significant.
RESULTS
The 39 patients ranged in age from 40 to 72 yr (mean,
53.15 yr). There were 22 females and 17 males. 
Thirty-one cases were stage IIB (high grade with an extra
compartment) according to the Musculoskeletal Tumor Soci-
ety Staging System (5) and 8 cases were stage III (any grade
with metastasis). The tumors were located on the bones of
the extremities in 31 (79.5%) and on the axial bones in 8
(20.5%) patients. In the extremities, the most common loca-
tion was the distal femur (n=12, 30.8%), followed by the
proximal tibia (n=8, 20.5%), proximal femur (n=7, 18.0%),
humerus (n=2, 5.1%) and others (n=2, 5.1%). For the axial
bones, the most common site was the pelvis (n=7, 18.0%),
which was followed by the sacrum (n=1, 2.6%). 
Thirty-seven of the 39 cases were available to study the size
of the lesion, which ranged in size from 6 to 23 cm, and the
size was more than 10 cm in the greatest dimension in 24
(64.9%) cases, whereas the size was less than 9 cm in diam-
eter in 13 (35.1%).
The radiological findings were interesting. Twenty-nine
patients had radiographs available for study or an adequate
detailed description in their medical records. According to
these, 19 cases (65.5%) showed osteolytic lesions, 3 cases
(10.4%) showed osteoblastic lesions, and 7 cases (24.1%)
showed a mixed pattern. Periosteal reactions were observed
in only 6 cases (20.7%).
The initial serum alkaline phosphatase level could be re-
viewed in 30 cases. Twenty-two cases had lower levels than
the normal range, and 8 cases had higher levels.
Eleven cases (39%) were initially misdiagnosed. Misdiag-
noses included a simple fracture (3 cases), giant cell tumor
(3 cases), infection (2 cases), metastatic tumor (2 cases) and
myositis ossificans (1 case). Misdiagnosed 11 patients were
Variable  No. of patients (%)  p value 
Sex 
Male 17 (43.6%) 0.9776
Female 22 (56.4%)
Location 0.86
Distal femur 12 (30.77%)
Proximal femur 7 (17.95%)
Proximal tibia 8 (20.51%)
Pelvis 7 (17.95%)
Sacrum 1 (2.56%)
Humerus 2 (5.13%)
Others 2 (5.13%)
Size (37 cases) 0.12
≥10 cm 24 (64.9%)
<10 cm 13 (35.1%)
Chemotherapy (22 cases) 0.56
Complete 16 (72.7%)
Incomplete 6 (27.3%)
Alkaline Phosphatase (30 cases) 0.25
≥Normal 8 (26.7%)
<Normal 22 (73.3%)
Radiological findings (29 cases) 0.09
Osteolytic 19 (65.5%)
Osteoblastic 3 (10.4%)
Mixed 7 (24.1%)
Surgical margin (33 cases) 0.09
Wide excision 29 (87.8%)
Marginal excision 2 (6.1%)
Intralesional excision 2 (6.1%)
Chemotherapy-induced tumor necrosis *
Good responder 3 (16.7%)
Poor responder 15 (83.3%)
Table 1. Clinical data of 39 old age patients
*Statistical evaluation is not available on account of the disproportionate
number of patients.
Variable  Older patients Adolescent patients p value 
Location 0.035
Extremity 31 (79.5%) 41 (95.3%)
Axial Bone 8 (20.5%) 2 (4.7%)
Radiological findings  0.031
Osteolytic 19/29 (65.5%) 10/43 (23.3%)
Osteoblastic 3/29 (10.4%) 27/43 (62.8%)
Mixed 7/29 (24.1%) 5/43 (13.9%)
Chemotherapy-induced tumor necrosis 0.035
Good responder 3 (16.7%) 18 (42.2%)
Poor responder 15 (83.3%) 25 (57.8%)
Table 2. Statistically significant comparisons between older pa-
tients and adolescent patientsOsteosarcoma in Older Patients 717
treated with routine conventional protocols, which we pro-
vide.
Complete chemotherapy treatment was defined as com-
pletion of chemotherapy to over 75% of the predetermined
dosage. Chemotherapy was given to 22 patients. Complete
chemotherapy was given to 16 of 22 patients, and incom-
plete therapy was given to 6 patients. Chemotherapy was
not administered to 17 patients as a result of their poor sys-
temic condition.
A documented grading of tumor necrosis after preopera-
tive chemotherapy was available in 18 patients. Using tumor
necrosis at or above 90%, which is consistent with an effec-
tive response induced by chemotherapy; a good grade of an
effective response was observed in 3 cases (16.7%) and a poor
grade was observed in 15 (83.3%) cases. 
Thirty-three cases underwent surgery; 29 of the 33 cases
underwent a wide excision; 6 cases developed a local recur-
rence after surgery. Four cases underwent a marginal or intra-
lesional excision; 2 of these cases developed a local recurrence.
The remaining 6 cases were treated without surgery due to
an inoperable local condition or poor systemic condition.
The institutional review of primary osteosarcoma in the
older patients did not reveal any significant prognostic vari-
ables in terms of the gender, tumor location, tumor size, ini-
tial serum value for alkaline phosphatase, radiological find-
ings, surgical margin, chemotherapy intensity and chemo-
therapy-induced tumor necrosis rate (Table 1).
In a comparative study, the tumor location, chemothera-
py-induced tumor necrosis and radiological findings for the
older patients were statistically different from the adolescent
patients (Table 2). 
For 31 cases in stage IIB, the actual 5 yr survival rate was
44.3%, and the disease free survival rate was 26.7%. Fifteen
of the 31 cases developed metastases, which was detected from
2.8 to 74.5 months after the initial diagnosis (mean 19.8
months). For 8 cases in stage III, the actual 5 yr survival rate
was 12.5%. The event free survival in the older patients was
17.8% at 110 months. 
DISCUSSION
Most osteosarcoma patients are adolescents but there is an
increasing incidence of older patients with osteosarcoma (6).
Therefore, an analysis of older patients with osteosarcoma is
noteworthy. Information regarding the clinical outcome of
older patients with osteosarcoma has been based on reports
from the United States and Europe; they indicate that most
older patients with osteosarcomas have them as secondary
lesions (2, 3). However, a secondary osteosarcoma is rare in
Asian countries. Most older patients with osteosarcoma in
Asian countries are considered to be primary osteosarcoma. A
few Asian reports (7, 8) have revealed the characteristics of older
patients with osteosarcoma. According to the report by Naka
et al., including secondary osteosarcoma, age is not a poor
prognostic factor and older patients should be treated similarly
to younger patients with aggressive chemotherapy and com-
plete surgical excision whenever possible (7). However, his
paper was not based only on primary de novo osteosarcoma.
In 1999, Rhee et al. (9) evaluated 11 older patients with
primary osteosarcoma, and concluded that there was no sig-
nificant poorer survival by age among patients. However,
they reported that the radiological patterns of multiple osteo-
lytic lesions, and the predominantly fibroblastic appearance
of tumors were particularly prevalent among older patients.
Their findings were similar with this study but their results
were not consistent with the results of this study. The differ-
ent results might be due to a smaller study population as well
as the inclusion of two patients with stage I osteosarcoma in
Fig. 1. Anteroposterior
radiography shows an
osteolytic lesion without
periosteal reaction of
the proximal tibia. This
lesion was misdiagnos-
ed as a giant cell tumor
before biopsy. 
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Fig. 2. Kaplan-Meier curve between old age and adolescents pa-
tients shows significant differences. Older patients had a poorer
prognosis.718 D.G. Jeon, S.Y. Lee, W.H. Cho, et al.
Rhee et al.
In contrast to osteosarcoma in adolescents, occurrences in
the axial bone (20.5% vs. 4.7%) were not uncommon. The
tumor was more commonly located in the axial bones of the
older patients than in the adolescent patients (p=0.035).
Because of the characteristic site distribution, surgical treat-
ment in the older patients is technically more difficult. The
radiological characteristics of a primary osteosarcoma in older
patients are probably associated with the frequent misdiag-
noses. There was a predominance of osteolytic lesions and a
frequent absence of a periosteal reaction (65.5%). In 3 cases,
misdiagnosed as a giant cell tumor, the radiological features
were quite similar to those of a typical giant cell tumor, show-
ing osteolytic lesions without periosteal reaction (Fig. 1). These
characteristic radiological features might be associated with
the frequent misdiagnosis in this group. 
In addition, the unusual sites of an osteosarcoma in older
patients may also lead to a misdiagnosis. Therefore, the pos-
sibility of a primary osteosarcoma should be considered for
osteolytic lesions without periosteal reactions in older patients,
even though other diagnoses are more common in this age
group.
Regarding the chemotherapy-induced tumor necrosis,
42.2% were good responders in the adolescent group but
only 16.7% were good responders in the older patients (p=
0.035). Preoperative chemotherapy was supplied in 18 pati-
ents, and the effect was poor in 15 (83.3%) of those. The poor
response to chemotherapy might be due to a difference in
tumor biology. Although, the meaning of the serum alkaline
phosphatase level varies (10, 11), the high rate of low alkaline
phosphatase levels and the low rate of osteoblastic radiologi-
cal findings in this group may be related to this. According
to Huvos (3), the subclassification of an osteosarcoma by his-
tology examination revealed a clear preponderance of fibro-
histiocytic and fibrous variants (38.5%). We suspect that os-
teosarcomas in older patients might have a different patho-
logic trend and this phenomenon produced different radiolog-
ical features. However, this point is not certain until more
detailed study is developed in the future. In addition, it is
widely accepted that the pharmacokinetics in patients with
an osteosarcoma are age related (12), and that the side effects
associated with chemotherapy are more prominent in older
patients (13).
This paper examined only primary osteosarcoma in older
patients. According to our results, older patients have a poorer
prognosis than adolescents. The overall survival and event
free survival rate in older patients was 39.5% at 104 months
and 17.8% at 110 months. In contrast, it was 70.1% at 228
months and 61.6% at 228 months in adolescents (p<0.001)
(Fig. 2).
The poor survival in older patients is most likely associat-
ed with a combination of unusual tumor locations, delayed
diagnosis due to unusual radiological findings, difficulties
with surgery and administration and poor response to chemo-
therapy. Therefore, careful attention should be paid to mak-
ing an accurate diagnosis. In addition, new strategies includ-
ing modified chemotherapy regimens will be needed to achieve
a long-term survival for older patients with osteosarcoma.
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